NCT07042698

Brief Summary

Glomerular filtration rate (GFR), which is the main biomarker used in clinical practice to assess kidney function, is usually estimated from the serum concentration of endogenous markers such as creatinine and/or cystatin C. GFR estimation equations all share the disadvantage of imperfect accuracy due to non-GFR-related determinants of creatinine and cystatin C. When knowing the exact GFR value is necessary for clinical decision-making, measurement by clearance of an exogenous tracer is required. Various tracers are available, some of which are radioactive tracers (99mTc-DTPA and 51Cr-EDTA), while others are iodinated contrast agents (iohexol, iothalamate). GFR measurement procedures are time-consuming and require significant human resources (4 to 5 hours, or even 24 hours for plasma clearances at very low GFR values).Urinary clearance methods may be inaccurate in cases of inadequate voiding. Plasma clearance results may be inaccurate in cases of increased (overestimation) or decreased (underestimation) extracellular volume, low GFR (unless late sampling is performed), or glomerular hyperfiltration. Measuring tracers requires either warm labs for measuring radioactive markers or labs with HPLC (High Performance Liquid Chromatography) chains for iohexol, which are part of an external quality assurance program. The complexity and/or length of GFR measurement procedures, their cost, and laboratory constraints explain why measured GFR is underused in routine clinical practice. There is a critical need to develop GFR measurement methods that are simpler to implement, reliable across the entire GFR spectrum, and widely available. We have demonstrated that it is possible to measure GFR using 4-phase CT urography performed as part of the care of living kidney donor candidates (healthy individuals with normal GFR). The examination takes 10 minutes, requires no biological sampling, and is not subject to potential inaccuracies due to sodium overload or poor bladder emptying.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
14mo left

Started Jul 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress41%
Jul 2025Jul 2027

First Submitted

Initial submission to the registry

June 17, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

June 29, 2025

Completed
16 days until next milestone

Study Start

First participant enrolled

July 15, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 14, 2027

Expected
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2027

Last Updated

June 29, 2025

Status Verified

June 1, 2025

Enrollment Period

2 years

First QC Date

June 17, 2025

Last Update Submit

June 25, 2025

Conditions

Keywords

Glomerular Filtration RateTomographyX-Ray Computed

Outcome Measures

Primary Outcomes (1)

  • Assessment of the Reliability of GFR Measurement by 4-Phase CT Urography Compared to Iohexol Clearance

    To assess whether GFR measurement using 4-phase CT urography is reliable in patients with GFR below 60 ml/min/1.73 m², as compared with iohexol clearance (reference method): - Unbiased (mean difference between CT-measured GFR and iohexol clearance not different from zero). - and accurate: at least 50% and 80% of GFR values measured by CT urography within 10% and 20% of biological clearance values for iohexol clearance.

    Day 1

Secondary Outcomes (3)

  • Reliability Assessment of GFR Estimation Using Creatinine and/or Cystatin C Compared to Iohexol Clearance

    Day 1

  • Reliability of Hybrid GFR (Mean of CT-Measured and Creatinine/Cystatin C Estimated GFR)

    Day 1

  • Reliability of CT-Measured GFR Across Patient Subgroups Defined by Estimated GFR Ranges

    Day 1

Study Arms (1)

GFR Measurement Using 4-Phase CT Urography and Comparison with Iohexol Clearance

OTHER

A study with one arm, adding experimental procedures to standard of care (a 4-phase CT urography and biological sampling) in order to evaluate the accuracy of GFR measurement by CT urography in patients with chronic kidney disease.

Other: Glomerular Filtration Rate measurement with iohexol clearance

Interventions

After performing a 4-phase CT urography (or 3-phase CT scan, with the addition of a 4th phase for research purposes), performed for clinical indications as part of the patient's care, and using iohexol as a contrast agent, patients will undergo a biological measurement of iohexol clearance, based on serum and urine samples taken over 4 periods of 1 hour, between 3 and 7 hours after the CT scan. No iohexol will be reinjected to measure GFR. The CT scan images will be segmented by the investigator to determine the CT-measured GFR.

GFR Measurement Using 4-Phase CT Urography and Comparison with Iohexol Clearance

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients older than 18 years of age
  • Having given written consent to participate in the study
  • Patient referred to the medical imaging department of the Henri Mondor University Hospital for a 3-phase or 4-phase abdominal CT scan
  • With an estimated GFR according to CKD-EPIcreat2009 \< 60 ml/min/1.73m²
  • Hospitalized or outpatient
  • Affiliated with French national health insurance

You may not qualify if:

  • Patients with hip implants, due to artifacts that make quantification of the contrast agent in the bladder unreliable
  • Lack of health insurance
  • Patients under legal protection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assistance Publique Hôpitaux de Paris - CHU Henri Mondor - Créteil

Créteil, Île-de-France Region, 94000, France

Location

MeSH Terms

Conditions

Kidney Diseases

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Central Study Contacts

Thomas STEHLE, Dr

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 17, 2025

First Posted

June 29, 2025

Study Start

July 15, 2025

Primary Completion (Estimated)

July 14, 2027

Study Completion (Estimated)

July 15, 2027

Last Updated

June 29, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION

Locations